Try our beta test site
10 studies found for:    weill | Open Studies | "Gastroenteritis"
Show Display Options
Rank Status Study
1 Not yet recruiting Triage Administration of Ondansetron for Gastroenteritis in Children
Condition: Gastroenteritis
Interventions: Drug: Ondansetron;   Drug: Placebos
2 Not yet recruiting Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Conditions: Crohn's Disease;   Spondyloarthritis
Intervention: Other: No intervention
3 Recruiting Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Condition: Crohn Disease
Intervention: Drug: etrolizumab
4 Recruiting A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Etrolizumab 210 mg;   Drug: Etrolizumab 105 mg;   Drug: Placebo
5 Recruiting A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: GED-0301;   Other: Placebo
6 Recruiting Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: GED-0301;   Drug: Placebo
7 Recruiting A Study of LY3074828 in Participants With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: LY3074828;   Drug: Placebo
8 Recruiting A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: Etrozulimab;   Drug: Placebo
9 Recruiting A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Condition: Colitis, Ulcerative
Interventions: Drug: Etrolizumab;   Drug: Placebo
10 Recruiting Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
Condition: Ulcerative Colitis
Intervention: Drug: Etrolizumab

Study has passed its completion date and status has not been verified in more than two years.